文献速递消化道肿瘤与早癌炎症性肠病

肿瘤分泌的细胞外囊泡调控T细胞共刺激并可用于诱导肿瘤特异性T细胞应答

Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.
PubMed 文献 · Gastroenterology · 2021-04-23

该研究探讨了结直肠癌肿瘤细胞分泌的细胞外囊泡(EVs)对CD28-CD80/86共刺激通路的影响及其在免疫检查点阻断(ICB)抵抗中的作用。研究发现,含miR-424的肿瘤EVs抑制T细胞和树突状细胞的共刺激通路,导致ICB抵抗;而敲低miR-424的修饰EVs可增强T细胞抗肿瘤免疫并提高ICB反应,在晚期结直肠癌模型中诱导肿瘤抗原特异性免疫应答。

要点

  • 肿瘤分泌的EVs通过miR-424抑制CD28-CD80/86共刺激通路,导致ICB抵抗。
  • 敲低miR-424的修饰EVs可增强T细胞抗肿瘤免疫并提高ICB疗效。
  • 修饰EVs在晚期结直肠癌模型中诱导肿瘤抗原特异性免疫应答。

核心结论

  • 肿瘤分泌的EVs在抗肿瘤免疫调节和免疫治疗反应中起关键作用,可能成为ICB抵抗性结直肠癌的新治疗手段。

研究设计与样本

  • 研究使用人结直肠癌免疫特征分析、小鼠肿瘤样本、细胞系、人结直肠癌类器官及多种同系原位晚期结直肠癌小鼠模型。
  • 通过分析肿瘤-免疫细胞相互作用和EVs功能,评估其对CD28-CD80/86通路及ICB反应的影响。

主要发现

  • 含miR-424的肿瘤EVs抑制肿瘤浸润T细胞和树突状细胞的CD28-CD80/86共刺激通路,导致ICB抵抗。
  • 敲低miR-424的修饰肿瘤EVs增强T细胞介导的抗肿瘤免疫反应并提高ICB反应。
  • 静脉注射修饰EVs在模拟侵袭性晚期疾病的结直肠癌模型中诱导肿瘤抗原特异性免疫应答并增强ICB疗效。

临床怎么用

  • 修饰肿瘤EVs(敲低miR-424)可能作为ICB抵抗性结直肠癌的新型治疗策略。
  • 需进一步临床验证EVs调控共刺激通路在结直肠癌免疫治疗中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Colorectal cancer is a major cause of cancer-related deaths worldwide. Immune checkpoint blockade therapies are effective in 30%-60% of the microsatellite instable-high subtype. Unfortunately, most patients with colorectal cancer (>85%) have microsatellite stable tumors that do not respond. In this study, we aimed to decipher the underlying tumor-intrinsic mechanisms critical for improving immunotherapy in colorectal cancer. METHODS: We used human and mouse tumor samples, cell lines, human colorectal cancer organoids, and various syngeneic orthotopic mouse models of late-stage colorectal cancer to define the effects of tumor cell-secreted extracellular vesicles (EVs) on antitumor immune response. RESULTS: Our analyses of human colorectal cancer immune profiles and tumor-immune cell interactions showed that tumor-secreted EVs containing microRNA miR-424 suppressed the CD28-CD80/86 costimulatory pathway in tumor-infiltrating T cells and dendritic cells, leading to immune checkpoint blockade resistance. Modified tumor-secreted EVs with miR-424 knocked down enhanced T-cell-mediated antitumor immune response in colorectal cancer tumor models and increased the immune checkpoint blockade response. Intravenous injections of modified tumor-secreted EVs induced tumor antigen-specific immune responses and boosted the immune checkpoint blockade efficacy in colorectal cancer models that mimic aggressively progressing, late-stage disease. CONCLUSIONS: Collectively, we show a critical role for tumor-secreted EVs in antitumor immune regulation and immunotherapy response, which could be developed as a novel treatment for immune checkpoint blockade-resistant colorectal cancer.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Zhao X, Yuan C, Wangmo D, et al. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses. Gastroenterology. 2021. PMID: 33895168. doi:10.1053/j.gastro.2021.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。